Agency Business briefs

Share this article:
GCI Health named Wendy Lund CEO, a new position. Lund joins GCI from MS&L, where she was EVP, global business and client development and a member of the global leadership team. She was also CEO of Publicis Consultants PR, an MS&L sibling shop. GCI Health was spun off as an independent unit in 2008 following GCI Group's merger with Cohn & Wolfe. Jill Dosik continues as president.

Roska Healthcare Advertising president Jay Bolling (below) has bought out founder Jon Roska and taken on the role of chief executive at the independent agency. Based in Montgomeryville, PA, Roska Healthcare Advertising clients include Pfizer, Bristol-Myers Squibb and GlaxoSmithKline.

Heartbeat Digital spun off its software division, Heartbeat Software, into an independent company, citing differing missions, business structures and marketing plans as well as a lack of shared back office and support services.

Draftfcb Healthcare named Rich Levy EVP, chief creative officer. Levy joined Draftfcb from GSW Worldwide, where he was executive creative director, and will take on some of the responsibilities held by chairman emeritus Tom Domanico, who retired last year.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?